Gomeisa (Escitalopram Oxalate)

Gomeisa is indicated for the management of several psychiatric conditions where serotonin modulation is beneficial. Clinical use is guided by diagnosis and patient response and.

• Major depressive disorder, characterized by persistent low mood and loss of interest.
• Generalized anxiety disorder, involving excessive and uncontrollable worry.
• Social anxiety disorder, marked by intense fear of social situations.
• Panic disorder, featuring recurrent unexpected panic attacks.
• Off‑label use may be considered for other anxiety‑related conditions under specialist supervision.

Side effects of Gomeisa vary in frequency and severity. They are grouped into common reactions that are usually mild and serious events that require medical attention.

Common

• Nausea or upset stomach.
• Headache.
• Dry mouth.
• Insomnia or drowsiness.
• Increased sweating.

Serious

• Suicidal thoughts or behavior, especially in young adults.
• Serotonin syndrome, presenting with agitation, fever, and rapid heart rate.
• Severe allergic reaction such as rash, itching, or swelling.
• Abnormal heart rhythm (QT prolongation) in susceptible individuals.
• Low sodium levels (hyponatremia) that may cause confusion.

Before starting Gomeisa, certain health considerations should be reviewed to minimize risks and ensure safe use in clinical practice.

• History of bipolar disorder or mania, as SSRIs can trigger mood switching.
• Existing liver or kidney impairment, which may affect drug metabolism.
• Pregnancy or breastfeeding status, because safety data are limited.
• Use of other serotonergic agents, increasing risk of serotonin syndrome.
• Elderly patients, who may be more sensitive to side effects such as hyponatremia.
• Presence of uncontrolled hypertension or cardiac arrhythmias.
• Known hypersensitivity to escitalopram or any excipients.

Gomeisa can interact with other medicines, altering its effectiveness or increasing the chance of adverse reactions. Awareness of these interactions helps guide therapy.

Avoid

• Monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI, due to risk of serotonin syndrome.
• Other SSRIs, SNRIs, or tramadol, which can also raise serotonin levels.
• Certain antiarrhythmic drugs that may prolong QT interval when combined.

Use with caution

• Anticoagulants or antiplatelet agents, as escitalopram may increase bleeding risk.
• NSAIDs or aspirin, which can also affect platelet function.
• CYP2C19 inhibitors (e.g., fluoxetine, omeprazole) that may raise escitalopram concentrations.
• Alcohol, which can enhance central nervous system depression.
• Herbal supplements such as St. John’s wort, which have serotonergic activity.